<DOC>
	<DOC>NCT00768664</DOC>
	<brief_summary>This study will investigate the safety and efficacy of oral PF-00299804 in patients who have not yet undergone any other drug treatment for recurrent and/ or metastatic head and neck squamous cell cancer.</brief_summary>
	<brief_title>Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms, Squamous Cell</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<criteria>Recurrent or metastatic Squamous Cell Cancer of the Head and Neck; Measurable disease; Eastern Cooperative Oncology Group (ECOG) 01 in Stage 1 = first 23 patients; Eastern Cooperative Oncology Group (ECOG) 02 in Stage 2 = 33 patients; prior therapy for recurrence; platelets &lt; 75,000; prior Epidermal Growth Factor Receptor (EGFR) therapy; interstitial lung disease; primary of nasopharynx</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>recurrent or metastatic squamous cell cancer of the Head and Neck; no prior systemic therapy for recurrence</keyword>
</DOC>